Cardiovascular Outcomes
Cardiovascular outcome evidence in diabetes and metabolism, including MACE, heart failure, renal outcomes, lipid therapy, hypertension, and cardiometabolic risk reduction.
Intensive Blood Pressure Control (<120 mmHg) Reduces CV Events in Type 2 Diabetes: Chinese BPROAD Trial
In patients with type 2 diabetes, intensive blood-pressure control (targeting systolic BP
Oral Semaglutide Proven Cardiovascular Safe for High-Risk Type 2 Diabetes Patients
In patients with type 2 diabetes at high cardiovascular (CV) risk, oral semaglutide demonstrated non-inferior cardiovascular safety to placebo, showing no significant increase in major adverse cardiovascular events (MACE), which included cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.
Study Finds Semaglutide Reduces Cardiovascular Risk in Type 2 Diabetes Patients, but Raises Retinopathy Concerns
In patients with type 2 diabetes and high cardiovascular risk, once-weekly semaglutide significantly reduced the risk of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) compared to placebo, though it was associated with a higher risk of diabetic retinopathy complications.